Moleculin Biotech CS (NASDAQ:MBRX) up 14.29% to close at the price of $2.08. The stock has a market capitalization of $44.74 Million however its outstanding shares are 21.51 Million. The company’s beta value stood at 0.

Taking a broader look at the analyst consensus, brokerage firms have a price target of $9.26 on Moleculin Biotech CS (NASDAQ:MBRX). Brokerage firms on the street have price targets on the name ranging from $9.26 to $9.26 based on 1 opinions.

Moleculin Biotech CS (NASDAQ:MBRX) as of current trade, has shown weekly performance of 21.64% which was maintained at 10.64% in one month period. Year to date performance remained at -8.77%. During the past three months the stock gain -22.39%, however six months performance of the stock remained at 160%. Moleculin Biotech CS (NASDAQ:MBRX)’s price sits 3.51% above from its SMA 50 of $1.83 and 26.3% far from the SMA 200 which is at $1.94.

Currently Moleculin Biotech CS (NASDAQ:MBRX)’s shares owned by insiders are 17.7%, whereas shares owned by institutional owners are 3.1%. However the six-month change in the insider ownership was recorded -4.99%, as well as three-month change in the institutional ownership was recorded -36.66%.

The stock is trading -44.53% away from its 52 week high of $3.75 and 194.45% far from the stock’s low point over the past 52 weeks, which was $0.71.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Moleculin Biotech CS (NASDAQ:MBRX)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Moleculin Biotech CS (NASDAQ:MBRX) has a current PEG of 0. Moleculin Biotech CS (NASDAQ:MBRX)’s price to sales ratio for trailing twelve month stands at 0, whereas its price to book ratio for the most recent quarters is at 1.93. However the company’s price to cash per share for most recent quarter stands at 0.43. Its price to free cash flow for trailing twelve months is 4.81.